المؤلفون: Priotto G; Epicentre, Paris, France. gpriotto@epicentre.msf.org, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande V

المصدر: Lancet (London, England) [Lancet] 2009 Jul 04; Vol. 374 (9683), pp. 56-64. Date of Electronic Publication: 2009 Jun 24.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Trypanosoma brucei gambiense*, Eflornithine/*therapeutic use , Nifurtimox/*therapeutic use , Trypanocidal Agents/*therapeutic use , Trypanosomiasis, African/*drug therapy, Administration, Oral ; Adult ; Animals ; Congo/epidemiology ; Democratic Republic of the Congo/epidemiology ; Drug Administration Schedule ; Drug Therapy, Combination ; Eflornithine/adverse effects ; Female ; Fever/chemically induced ; Follow-Up Studies ; Humans ; Infections/chemically induced ; Infusions, Intravenous ; Kaplan-Meier Estimate ; Male ; Nifurtimox/adverse effects ; Safety ; Seizures/chemically induced ; Treatment Outcome ; Trypanocidal Agents/adverse effects ; Trypanosomiasis, African/diagnosis ; Trypanosomiasis, African/epidemiology